Rocket One Inc. 10-K

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Hoth Therapeutics, Inc. Consolidated Financial Statements TABLE OF CONTENTS Page No. Consolidated Financial Statements Report of Independent Registered Public Accounting Firm (PCAOB ID: 100) F- 2 Consolidated Balance Sheets as of December 2024 and 2023 F- 4 Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 F- 5 Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2024 and 2023 F- 6 Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 F- 7 Notes to Consolidated Financial Statements F- 8 F- 1 Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of Hoth Therapeutics, Inc. Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Hoth Therapeutics, Inc. (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America. Restatement of Prior Period Consolidated Financial Statements and the Unaudited Interim Condensed Consolidated Financial Statements As discussed in Note 8 to the consolidated financial statements, the accompanying 2023 consolidated financial statements have been restated to correct certain misstatements. Additionally, the Company has restated its unaudited interim condensed consolidated financial statements previously reported in the Forms 10-Q for the quarters ended March 31, 2023 and 2024, June 30, 2023 and 2024, and September 30, 2023 and 2024, as these interim periods were also affected by the errors. Our opinion is not modified with respect to the restatements. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. Research and Development Expenses, Accrued Clinical Trial Liabilities, and Prepaid Research and Development Costs F- 2 Description of the Matter The Company recognizes research and development expenses as incurred. Advance payments for future research and development activities are deferred and expensed as the related services are performed. The Company recognizes its clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations (collectively, "CROs") that conduct and manage clinical trials on the Company's behalf. The Company works closely with its CROs to reconcile prepaid research and development costs and accrued clinical trial prepaid expenses and liabilities by obtaining reporting from the CROs, discussing progress or stage of completion of services with internal personnel and external service providers, and comparing this information to payments made, invoices received, and the agreed-upon fees to be paid for such services in the applicable contract, statements of work, or purchase orders. The reconciliation of the amount of work completed is primarily based on the status and timing of services performed and the completion of project milestones. We identified research and development expenses, accrued clinical trial liabilities, and prepaid research and development costs as a critical audit matter given the estimation involved in accounting for research and development expenses, accrued clinical trial liabilities, and prepaid research and development costs. In addition, as described in Note 8 to the consolidated financial statements, the Company identified errors in the accounting for advance payments to a clinical research organization (CRO) during the 2024 audit which arose from expensing advance payments in full upon payment rather than recording them as prepaid expenses and recognizing the expense as services were performed. The errors led to a material overstatement of research and development (R&D) expenses and an understatement of prepaid expenses in the affected periods. This required extensive audit effort related to the estimation of research and development expenses, accrued clinical trial liabilities and prepaid clinical expenses and the complexity involved in determining the completeness and accuracy of the restated annual and interim financial data. How We Addressed the Matter in Our Audit Our audit procedures related to research and development expenses, accrued clinical trial liabilities, and prepaid clinical expenses included selecting a sample of amounts recognized as research and development expense, accrued clinical trial liabilities and prepaid research and development expenses and performing the following procedures for each item selected: ● We obtained and read related master service agreements, statements of work, purchase orders and/or other supporting agreements with the CROs. ● We performed corroborating inquiries with the Company's operations personnel responsible for the oversight of activities regarding the nature and status of work performed under the various CRO agreements. ● We inspected evidence from the third-party vendors regarding the payments made and the status and timing of services performed. In addition, we obtained confirmations from selected CROs related to billings incurred, balances due, work performed, and remaining advance balances. ● We compared the data and evidence obtained from internal and external sources to the inputs used in the Company's analysis and recalculated the related research and development expense, prepaid research and development expense, and the accrued clinical liabilities balance. ● We evaluated the Company’s process for identifying and correcting the prior period errors by testing the restated annual and quarterly amounts, including agreeing the corrected balances to underlying CRO contracts, payment records, and service performance timelines. /S/ WithumSmith+Brown , PC We have served as the Company’s auditor since 2018. New York, New York March 28, 2025 PCAOB ID No. 100 F- 3 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS December 31, December 31, 2024 2023 (As Restated) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 7,038,923 $ 9,292,352 Prepaid expenses and other current assets 605,948 858,126 Total Current Assets 7,644,871 10,150,478 NON-CURRENT ASSETS: Operating lease right-of-use asset, net 31,075 55,165 Investment in joint ventures at fair value 36,819 37,400 Total Non-Current Assets 67,894 92,565 Total Assets $ 7,712,765 $ 10,243,043 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 412,071 $ 35,592 Accrued expenses 390,760 614,226 Operating lease liability, current portion 28,366 28,839 Total Current Liabilities 831,197 678,657 LONG-TERM LIABILITIES: Operating lease liability, less current portion 2,709 26,326 Total Long-Term Liabilities 2,709 26,326 Total Liabilities 833,906 704,983 Commitments and Contingencies (Note 6) STOCKHOLDERS’ EQUITY: Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized; 3,000,000 shares undesignated; 0 shares issued and outstanding as of December 31, 2024 and 2023 - - Series A Convertible Preferred Stock, $ 0.0001 par value; 5,000,000 shares designated; 0 shares issued and outstanding on December 31, 2024 and 2023 - - Series B Preferred Stock, $ 0.0001 par value; 2,000,000 shares designated; 0 shares issued and outstanding on December 31, 2024 and 2023 - - Common stock, $ 0.0001 par value; 50,000,000 shares authorized; 8,042,747 and 4,348,129 shares issued and outstanding as of December 31, 2024 and 2023, respectively 804 435 Additional paid-in capital 67,279,033 61,732,106 Accumulated deficit ( 60,410,041 ) ( 52,221,741 ) Accumulated other comprehensive income 9,063 27,260 Total Stockholders’ Equity 6,878,859 9,538,060 Total Liabilities and Stockholders’ Equity $ 7,712,765 $ 10,243,043 The accompanying notes are an integral part of these consolidated financial statements. F- 4 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the Year Ended December 31, 2024 2023 (As Restated) NET REVENUES $ - $ - OPERATING COSTS AND EXPENSES: Research and development expense 3,249,096 3,740,785 General and administrative expenses 4,966,336 4,212,189 Total operating expenses 8,215,432 7,952,974 LOSS FROM OPERATIONS ( 8,215,432 ) ( 7,952,974 ) OTHER INCOME (EXPENSES), NET: Unrealized loss on marketable securities - ( 209,320 ) Change in fair value of investment in joint venture ( 581 ) 4,400 Dividend and interest income 27,713 51,772 Total other income (expenses), net 27,132 ( 153,148 ) NET LOSS $ ( 8,188,300 ) $ ( 8,106,122 ) NET LOSS PER COMMON SHARE: Basic and diluted $ ( 1.28 ) $ ( 2.38 ) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: Basic and diluted 6,375,161 3,409,190 COMPREHENSIVE LOSS: Net loss $ ( 8,188,300 ) $ ( 8,106,122 ) Other comprehensive (loss) income: Foreign currency translation adjustment ( 18,197 ) 5,254 Total comprehensive loss $ ( 8,206,497 ) $ ( 8,100,868 ) The accompanying notes are an integral part of these consolidated financial statements. F- 5 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 Accumulated Common Stock Additional Paid-in Accumulated Deficit other Comprehensive Total Stockholders’ Shares Amount Capital (As Restated) Income (Loss) Equity Balance, December 31, 2022 (As Restated) 1,302,113 $ 130 $ 50,198,630 $ ( 44,115,619 ) $ 22,006 $ 6,105,147 Exercise of warrants 2,355,050 236 2,119 - - 2,355 Stock-based compensation - - 216,428 - - 216,428 Common stock and warrants issued in private placement, net of offering costs 689,275 69 11,314,929 - - 11,314,998 Vesting of restricted shares 1,691 - - - - - Cumulative translation adjustment - - - - 5,254 5,254 Net loss - - - ( 8,106,122 ) - (8,106,122 ) Balance, December 31, 2023 (As Restated) 4,348,129 435 61,732,106 ( 52,221,741 ) 27,260 9,538,060 Exercise of pre-funded warrants 55,675 5 ( 5 ) - - - Stock-based compensation - - 804,277 - - 804,277 Common shares issued for exercise of warrants, net of issuance costs 2,500,000 250 3,682,050 - - 3,682,300 Common stock issued for cash, net 1,137,250 114 1,060,605 - - 1,060,719 Vesting of restricted shares 1,693 - - - - - Cumulative translation adjustment - - - - ( 18,197 ) (18,197 ) Net loss - - - ( 8,188,300 ) - (8,188,300 ) Balance, December 31, 2024 8,042,747 $ 804 $ 67,279,033 $ ( 60,410,041 ) $ 9,063 $ 6,878,859 The accompanying notes are an integral part of these consolidated financial statements. F- 6 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS For the Year Ended December 31, 2024 2023 (As Restated) CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 8,188,300 ) $ ( 8,106,122 ) Adjustments to reconcile net loss to net cash used in operating activities: Gain on termination of license agreement - ( 275,000 ) Stock-based compensation 804,277 216,428 Unrealized loss on marketable securities - 209,320 Change in fair value of investment in joint ventures 581 ( 4,400 ) Changes in operating assets and liabilities: Prepaid expenses 252,178 213,432 Accounts payable and accrued expenses 153,013 ( 700,752 ) NET CASH USED IN OPERATING ACTIVITIES ( 6,978,251 ) ( 8,447,094 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock, common stock warrants and prefunded warrants, net of offering costs 1,060,719 11,314,998 Proceeds from exercise of warrants, net of issuance costs 3,682,300 2,355 NET CASH PROVIDED BY FINANCING ACTIVITIES 4,743,019 11,317,353 NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS ( 2,235,232 ) 2,870,259 Effect of exchange rate changes on cash and cash equivalents ( 18,197 ) ( 6,518 ) CASH AND CASH EQUIVALENTS - beginning of year 9,292,352 6,428,611 CASH AND CASH EQUIVALENTS - end of year $ 7,038,923 $ 9,292,352 NON-CASH INVESTING AND FINANCING ACTIVITIES: ROU assets obtained in exchange for lease liability $ - $ 59,698 The accompanying notes are an integral part of these consolidated financial statements. F- 7 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 NOTE 1 – Organization and Description of Business Operations Hoth Therapeutics, Inc. (together with its wholly-owned subsidiaries, merveille.ai and Hoth Therapeutics Australia Pty Ltd, the “Company”) was incorporated under the laws of the State of Nevada on May 16, 2017 . The Company is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing (i) a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); (ii) a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and (iii) a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for (i) atopic dermatitis (also known as eczema) (BioLexa); (ii) a treatment for asthma and allergies using inhalational administration (HT-004); and (iii) a treatment for obesity, and obesity-related diseases and conditions (HT-VA). Liquidity and Capital Resources Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements - Going Concern , requires management to evaluate the Company’s ability to continue as a going concern one year beyond the filing date of the given financial statements. This evaluation requires management to perform two steps. First, management must evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern. Second, if management concludes that substantial doubt is raised, management is required to consider whether it has plans in place to alleviate that doubt. Disclosures in the notes to the consolidated financial statements are required if management concludes that substantial doubt exists or that its plans alleviate the substantial doubt that was raised. The Company has funded its operations from proceeds from the sale of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan. The Company’s ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if it were successful, future equity issuances may result in dilution to its existing shareholders and future debt securities may contain covenants that limit the Company’s operations or ability to enter into certain transactions. The Company believes its current cash is sufficient to fund operations for at least the next 12 months from the issuance date of these financial statements. However, the Company will need to raise additional funding, through strategic relationships, public or private equity or debt financings, grants or other arrangements, to develop and seek regulatory approvals for the Company’s current and future product candidates. If such funding is not available, or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed. On November 8, 2024, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) under which the Company may offer and sell shares of its common stock having an aggregate sales price of up to $ 2,700,000 through Wainwright as the sales agent pursuant to the Company’s effective shelf registration statement on Form S-3, including an accompanying prospectus (File No. 333-272620), and a prospectus supplement dated November 8, 2024. Sales of shares of the Company’s common stock through Wainwright, if any, will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. Wainwright will use commercially reasonable efforts to sell shares of the Company’s common stock from time to time, based on instructions from the Company (including any price, time or size limits or other parameters or conditions the Company may impose). The Company will pay Wainwright a commission equal to 3.0 % of the aggregate gross proceeds from the sales of shares of the Company’s common stock sold through Wainwright under the ATM Agreement and will also reimburse Wainwright for certain specified expenses in connection with the ATM Agreement. The offering of shares pursuant to the ATM Agreement will terminate on the earlier of (1) the sale, pursuant to the ATM Agreement, of shares having an aggregate offering price of $ 2,700,000 and (2) the termination of the ATM Agreement by either the Company or Wainwright, as set forth therein. In February 2025, the amount that the Company could offer and sell pursuant to the ATM Agreement was increased to $ 5,000,000 . As of March 28, 2025, the Company has sold shares of its common stock having a total aggregate sales price of $ 2.7 million. F- 8 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 NOTE 2 – Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries, merveille.ai which was incorporated under the laws of Nevada on October 4, 2023 and Hoth Therapeutics Australia Pty Ltd, which was incorporated under the laws of the State of Victoria in Australia on June 5, 2019. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation, the valuation of modified warrants, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations may be affected. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents consist of bank accounts and highly liquid money funds and totaled $ 7,038,923 and $ 9,292,352 as of December 31, 2024 and 2023, respectively. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits at the three financial institutions the Company utilizes for its banking requirements. The Company’s foreign bank accounts are not subject to FDIC insurance. Cash held in foreign bank accounts totaled approximately $ 0.1 million and $ 0.1 million as of December 31, 2024 and 2023, respectively. Concentrations of Credit Risk and Off-Balance Sheet Risk The Company has significant cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $ 250,000 . Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurements , (“ASC-820”), provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The fair value of the Company’s assets and liabilities, which would qualify as financial instruments under ASC-Topic 820, approximates the carrying amounts represented in the Company’s consolidated balance sheets, primarily due to their short-term nature. F- 9 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. During the years ended December 31, 2024 and 2023, there were no changes in valuation techniques or transfers between Level 1, Level 2, and Level 3. Leases The Company determines if an arrangement is a lease at inception and classifies its leases at commencement. Operating leases are presented as right-of-use (“ROU”) assets and the corresponding lease liabilities are included in operating lease liability, current and lease liability, on the Company’s consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset, and lease liabilities represent the Company’s obligation to make lease payments in exchange for the ability to use the asset for the duration of the lease term. The Company has lease agreements which contain both lease and non-lease components, which it has elected to account for as a single lease component. As such, minimum lease payments include fixed payments for non-lease components within a lease agreement but exclude variable lease payments not dependent on an index or rate, such as common area maintenance, operating expenses, utilities, or other costs that are subject to fluctuation from period to period. Certain of the leases contain an option to extend the term of the lease. The option to extend a lease is included in the lease term only when it is reasonably certain that the Company will elect that option. Additionally, the Company does not record ROU assets or lease liabilities for short-term leases that have a term of twelve months or less at lease commencement. ROU assets and lease liabilities are recognized at the commencement date and determined using the present value of the future minimum lease payments over the lease term. The Company uses an incremental borrowing rate based on an estimated rate of interest for collateralized borrowing since the Company’s leases do not include an implicit interest rate. The estimated incremental borrowing rate considers market data, actual lease economic environment, and the lease term at commencement date. Investment in Joint Ventures Ownership interests in entities for which the Company has significant influence that are not consolidated are accounted for as equity method investments. SEC Staff Announcement: Accounting for Limited Partnership Investments (codified in ASC 323-30-S99-1) guidance requires the use of the equity method unless the investor’s interest “is so minor that the limited partner may have virtually no influence over partnership operating and financial policies.” The SEC staff’s position is that investments in limited partnerships of greater than 3 % to 5 % are considered more than minor and, therefore, should be accounted for using the equity method or fair value option. Investments accounted for using the equity method may be reported on a lag up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date. The determination of whether an investee’s results are recorded on a lag is made on an investment-by-investment basis. This investment in joint ventures is further described in Note 4 of these consolidated financial statements. F- 10 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Prepaid Expenses As of December 31, 2024 and 2023, prepaid expenses and other current assets consisted of the following: As of December 31, 2024 2023 Prepaid clinical trial expenses $ 476,235 $ 722,765 Prepaid insurance 28,479 57,766 R&D credit receivable 46,769 46,769 Other prepaid expenses 54,465 30,826 $ 605,948 $ 858,126 Accounts Payable For the year ended December 31, 2023, the Company’s subsidiary Hoth Therapeutics Australia Pty Ltd, recorded approximately a $ 260,000 gain due to a settlement agreement on a payable balance with Novotech, a clinical trial management vendor. The gain is recognized in the consolidated statements of operations and comprehensive loss following a manner consistent with how the expense was originally recorded. There was no such transaction in the year ended December 31, 2024. Research and Development Costs Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are accrued and then expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Stock-Based Compensation The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. Options are generally issued fully vested. The Company accounts for forfeited awards as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term. Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices. Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company grants restricted stock awards under its equity incentive plan. Restricted stock awards are granted to employees and non-employees. The restricted stock awards are measured based on the grant-date fair value. In general, the restricted stock awards vest over a service period of zero to three years. Stock-based compensation expense is generally recognized based on the straight-line basis over the requisite service period and forfeitures are accounted for as they occur. The Company has issued warrants to non-employees. The warrants are measured based on the grant-date fair value. In general, the warrants vest over a term of zero to ten years. Stock-based compensation expense is generally recognized based on the straight-line basis over the vesting term. Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. F- 11 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Net Loss per Share Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss: Year Ended December 31, Potentially dilutive securities 2024 2023 Warrants 5,203,243 4,213,515 Options 1,090,362 169,362 Non-vested restricted stock awards - 1,693 Total 6,293,605 4,384,570 Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and in accordance with ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”), and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued warrants that meet all of the criteria for equity classification, the warrants are recorded as a component of additional paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants are classified as liability and are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Comprehensive Income (Loss) Comprehensive income (loss) is composed of net loss and other comprehensive income (loss). During the years ended December 31, 2024 and 2023, other comprehensive (loss) income was attributable to foreign currency translation adjustments. Foreign Currency The reporting currency of the Company is the U.S. dollar. For the Company’s subsidiary with non-U.S. dollar functional currencies, assets and liabilities are translated into U.S. dollars at period-end exchange rates. Revenue and expenses are translated at the average exchange rates during the period. Equity transactions are translated using historical exchange rates. The resulting translation adjustments are recorded in accumulated other comprehensive income (loss) as a component of stockholders’ equity. Foreign currency translation adjustments arising from differences in exchange rates from period to period are recorded within "Accumulated other comprehensive income (loss)" in the consolidated balance sheets. Segment Reporting In November 2023, the FASB issued ASU 2023-07, Segment Reporting (ASC 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses among other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 on January 1, 2024. The Company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. In accordance with ASC 280, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company and decides how to allocate resources based on loss from operations, managing cash flows and evaluating research and development and general and administrative expenses. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similarities in economic characteristics such as nature of services and procurement processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying notes to consolidated financial statements. Recent Accounting Pronouncements Income Taxes (Topic 740) In December 2023, the FASB issued guidance within ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . The amendments in the ASU are intended to provide more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU requires disclosure in the rate reconciliation of specific categories as well as additional information for reconciling items that meet a quantitative threshold. F- 12 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 The ASU requires disclosure of the following information about income taxes paid on an annual basis: ● Income taxes paid (net of refunds received), disaggregated by federal and state taxes and by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than five percent of total income taxes paid (net of refunds received). ● Income tax expense (or benefit) from continuing operations disaggregated by federal and state jurisdictions. The ASU is effective for annual periods beginning after December 15, 2024. The amendments should be applied on a prospective basis. The Company believes the adoption of this ASU will not have any impact on the Company’s consolidated financial statements. Currently, management does not believe that any other recently issued, but not yet effective accounting pronouncements, if currently adopted, would have a material impact on the Company’s consolidated financial statements. NOTE 3 – License Agreements The following summarizes the Company’s research and development expenses for licenses acquired (including stock-based compensation) during the years ended December 31, 2024 and 2023: For the Year Ended December 31, 2024 2023 The George Washington University $ 13,620 $ 66,172 North Carolina State University 6,250 — Virginia Commonwealth University — ( 275,000 ) U.S. Department of Veteran Affairs 54,000 — University of Cincinnati 1,666 7,500 $ 75,536 $ ( 201,328 ) The George Washington University During the year ended December 31, 2024, the Company recorded expenses of $ 13,620 for license fees, including an expense of $ 7,661 for the year ended December 31, 2024 related to warrants granted to The George Washington University (“GW”) pursuant to the patent license agreement with GW dated February 1, 2020 (“GW Patent License Agreement”) and the patent license agreement with GW dated August 7, 2020 (“Second GW Patent License Agreement”). During the year ended December 31, 2023, the Company recorded expenses of $ 66,172 for license fees, including an expense of approximately $ 29,000 related to warrants granted to GW pursuant to the GW Patent License Agreement and the Second GW Patent License Agreement. The Company recorded an expense of $ 30,000 for a milestone payment pursuant to GW Patent License Agreement. The Company also recorded $ 7,500 for the year ended December 31, 2023 for license maintenance fees. North Carolina State University During the year ended December 31, 2024, the Company recorded expenses of $ 6,250 for license fees associated with the license agreement by and between the Company and North Carolina State University dated February 25, 2021. During the year ended December 31, 2023, the Company did not recognize any expenses for license fees associated with such license agreement. Virginia Commonwealth University During the year ended December 31, 2024, the Company did not recognize any expenses for license fees associated with the exclusive license agreement (the “VCU License Agreement”) by and between the Company and Virginia Commonwealth University (“VCU”) dated May 18, 2020 that was terminated August 16, 2023. During the year ended December 31, 2023, the Company recognized a gain of $ 275,000 for license fees associated with the VCU License Agreement. On August 16, 2023, the Company terminated the VCU License Agreement. As of December 31, 2023, the Company reversed its prior accrual of $ 150,000 for five years of annual minimum payments and $ 125,000 for annual maintenance fees. F- 13 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 U.S. Department of Veteran Affairs During the year ended December 31, 2024, the Company recognized expenses of $ 54,000 for license fees associated with the exclusive license agreement by and between the Company and the US Department of Veteran Affairs dated December 9, 2024. During the year ended December 31, 2023, the Company did not recognize any expenses for license fees associated with such license agreement. Chelexa Biosciences, Inc. and the University of Cincinnati During the years ended December 31, 2024 and 2023, the Company recognized expenses of $ 1,666 and $ 7,500 for license fees associated with the Assignment and Assumption Agreement by and between the Company and Chelexa Biosciences, Inc. dated May 14, 2020, respectively. NOTE 4 – Fair Value of Financial Assets and Liabilities The following table presents the Company’s assets and liabilities that are measured at fair value on December 31, 2024 and 2023: Fair value measured on December 31, 2024 Total at December 31, 2024 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Investment in joint ventures $ 36,819 $ — $ — $ 36,819 Fair value measured on December 31, 2023 Total at December 31, 2023 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Investment in joint ventures $ 37,400 $ — $ — $ 37,400 Level 3 Measurement The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis for the years ended December 31, 2024 and 2023: Investment in joint venture for the year ended December 31, 2024 and 2023 For the Year Ended December 31, 2024 2023 Investment in joint ventures at fair value – beginning of year $ 37,400 $ 33,000 Change in fair value of investment in joint ventures ( 581 ) 4,400 Investment in joint ventures at fair value – end of year $ 36,819 $ 37,400 F- 14 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Investment in Joint Ventures The Company has elected to measure the investment in joint ventures using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in other income (expenses), net in the consolidated statements of operations and comprehensive loss. The value at which the Company’s investment in joint ventures is carried on its books is adjusted to estimated fair value at the end of each quarter, taking into account general economic and stock market conditions and those characteristics specific to the underlying investments. Investment in Zylö Therapeutics In connection with the Company’s March 2020 underwritten public offering of shares of its common stock, on May 4, 2020, the Company purchased 120,000 shares of Zylö Therapeutics (“Zylö”) Class B common stock for $ 60,000 . On December 8, 2021, the Company entered into a third amendment (the “Zylö Amendment”) to the Exclusive Sublicense Agreement with Zylö originally dated August 19, 2019 (as amended, the “Exclusive Sublicense Agreement”), pursuant to which the Company licensed its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö. Pursuant to the Zylö Amendment, on December 6, 2021, Zylö issued the Company 100,000 shares of its Class B common stock. In addition, pursuant to the Zylö Amendment, within 90 days following a sale by Zylö of all of its assets and rights related to HT-005 to a third-party (a “Sale”), Zylö shall pay the Company a low single digit percent of the net proceeds received by it attributable to HT-005 in the United States and Canada and their respective territories (collectively, the “Territory”) for the purposes of therapeutic uses related to lupus in humans (the “Field”). After the Sale, any and all rights of the Company pursuant to the Exclusive Sublicense Agreement, including all amendments thereto, shall terminate. Furthermore, pursuant to the Zylö Amendment, following the date of the first commercial sale of HT-005 in the Territory, in the Field, Zylö shall pay the Company (i) a low single digit percent of the Net Sales (as defined in the Exclusive Sublicense Agreement) of HT-005 in the event HT-005 is sold in the Territory and (ii) a low double digit percent of any royalty that Zylö receives through the sublicense to a third-party based on Net Sales of HT-005 in the Territory which payments shall continue in each country in the Territory until expiration of the last-to-expire Valid Claim (as defined in the Exclusive Sublicense Agreement). Zylö conducted a 409A valuation of their Class B common stock in February 2024, and as of December 31, 2024 and 2023, valued its share price at $ 0.167 and $ 0.17 per share, respectively. This value was ratified by Zylö’s board of directors in February 2024 and December 2023, respectively. On February 23, 2024, the Company acquired 22,000 shares of Class B Common stock of Atticus Pharma, a subsidiary of Zylö Therapeutics, based upon a 1-for-10 ratio of current shares and was instructed, on July 3, 2024, that the 409A valuation of the shares was $ 79 , or $ 0.0036 per share, pursuant to the February 2024 valuation ratified by Zylö’s board of directors. The valuations reflect a probability-weighted present value of expected future investment returns considering certain possible outcomes and the rights of each class of Zylö’s and Atticus Pharma’s equity. The future values of the common stock under the various outcomes are discounted back to the valuation date at a risk-adjusted discount rate and probability weighted to determine the value for the Class B common stock. Significant unobservable inputs in the valuation include: (i) probabilities of each scenario, (ii) timing of occurrence, (iii) future valuation; (iv) and the risk-adjusted discount rate. The consolidated investment in Zylö was valued at $ 36,819 and $ 37,400 as of December 31, 2024 and 2023, respectively. F- 15 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 NOTE 5 – Stockholders’ Equity Preferred Stock The Company is authorized to issue up to 10,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, and shall have such designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions thereof as shall be determined at the time of issuance by the Company’s board of directors without further action by the Company’s shareholders. As of December 31, 2024 and 2023, 5,000,000 shares of the Company’s preferred stock have been designated as Series A Convertible Preferred Stock, 2,000,000 shares of the Company’s preferred stock have been designated as Series B Preferred Stock, and 3,000,000 shares of the Company’s preferred stock remain undesignated. Series A Convertible Preferred Stock The shares of Series A Convertible Preferred Stock, par value $ 0.0001 per share, are not mandatorily redeemable and do not embody an unconditional obligation to settle in a variable number of equity shares. As such, the shares of Series A Convertible Preferred Stock are classified as permanent equity on the consolidated balance sheets. The holders’ contingent redemption right in the event of certain deemed liquidation events does not preclude permanent equity classification. Further, the shares of Series A Convertible Preferred Stock are considered an equity-like host for purposes of assessing embedded derivative features for potential bifurcation. The embedded conversion feature is considered to be clearly and closely related to the associated convertible preferred stock host instrument and therefore was not bifurcated from the equity host. As of December 31, 2024 and 2023, no shares of Series A Convertible Preferred Stock were issued and outstanding. Series B Preferred Stock On November 2, 2022, the Company filed a Certificate of Designation of the Series B Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada to create a new class of Series B Preferred Stock, par value $ 0.0001 per share (the “Series B Preferred Stock”). The Certificate of Designation designated 2,000,000 shares of authorized preferred stock as Series B Preferred Stock. The Series B Preferred Stock was not entitled to receive dividends or any other distributions. The Series B Preferred Stock was entitled to ten votes per share and voted together with the Company’s issued and outstanding shares of common stock as a single class exclusively with respect to a proposal to increase the number of shares of common stock that the Company was authorized to issue, together with any ancillary or administrative matters necessary or advisable in connection with the implementation of such increase. The Series B Preferred Stock had no rights as to any distribution or assets of the Company upon liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company. As of December 31, 2024 and 2023, no shares of Series B Preferred Stock were issued and outstanding. F- 16 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Warrants 2023 On December 29, 2022, the Company entered into a securities purchase agreement with an accredited investor pursuant to which it sold (i) 140,000 shares of common stock, (ii) pre-funded warrants to purchase up to 1,860,000 shares of common stock (“December Pre-Funded Warrants”) and (iii) common stock warrants to purchase up to 2,500,000 shares of common stock (“December Common Stock Warrants”) at a purchase price of $ 5.00 per share and accompanying December Common Stock Warrants (less $ 0.001 for each December Pre-Funded Warrant), in a private placement, for aggregate gross proceeds of approximately $ 10 million, exclusive of placement agent commission and fees and other offering expenses. The closing of the offering occurred on January 3, 2023. Each December Common Stock Warrant is exercisable for a period of five and one-half years from the issuance date at an exercise price of $ 5.00 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis. Each December Pre-Funded Warrant is exercisable until exercised in full at an exercise price of $ 0.001 per share and may be exercised on a cashless basis. The measurement of fair value of the December Pre-Funded Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at January 3, 2023, the date of issuance (i.e., share price of $ 6.56 , exercise price of $ 0.001 , term of  30 years beginning January 3, 2023 (as these do not have an expiration date), volatility of  135.07 %, risk-free rate of  3.88 %, and expected dividend rate of  0 %). The grant date fair value of the December Pre-Funded Warrants was estimated to be $ 12.2  million on January 3, 2023 and was reflected within additional paid-in capital as the Pre-Funded Warrants were determined to be equity classified. The measurement of fair value of the December Common Stock Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at January 3, 2023, the date of issuance (i.e., share price of $ 6.56 , exercise price of $ 5.00 , term of  five and a half years  beginning January 3, 2023, volatility of  135.07 %, risk-free rate of  3.94 %, and expected dividend rate of  0 %). The grant date fair value of these December Common Stock Warrants was estimated to be $ 15.0  million on January 3, 2023 and is reflected within additional paid-in capital as of December 31, 2024 and 2023 as the December Common Stock Warrants were determined to be equity classified. As a result of exercising the December Pre-Funded Warrants on various dates in February 2023, the investor exercised all the December Pre-Funded Warrants for an aggregate of 1,860,000 shares of the Company’s common stock for aggregate net proceeds to the Company of $ 1,860 . In addition, pursuant to the terms of the offering, the Company issued the designees of the placement agent, Wainwright, warrants to purchase up to 100,000 shares of the Company’s common stock (“December Wainwright Warrants”). The December Wainwright Warrants had a determined fair value of $ 591,090 as of the date of issuance. The December Wainwright Warrants are exercisable for a period of five and one-half years from the issuance date at an exercise price of $ 6.25 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis. As the December Wainwright Warrants were issued for services provided in facilitating the private placement, the Company recorded the fair value of such December Wainwright Warrants as an equity issuance cost on the issuance date. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at January 3, 2023, the date of issuance (i.e., share price of $ 6.56 , exercise price of $ 6.25 , term of  five and a half years beginning January 3, 2023, volatility of  135.07 %, risk-free rate of  3.94 %, and expected dividend rate of  0 %). On September 13, 2023, the Company entered into a securities purchase agreement with certain institutional investors (the “September Investors”) pursuant to which it sold (i) 549,275 shares of common stock and (ii) pre-funded warrants (the “September Pre-Funded Warrants”) to purchase up to 550,725 shares of common stock at a purchase price of $ 2.63 per share of common stock and a purchase price of $ 2.629 per September Pre-Funded Warrant. Concurrently with the sale of common stock and/or the September Pre-Funded Warrants, pursuant to the securities purchase agreement, in a private placement, the Company issued and sold warrants (the “September Common Stock Warrants”) to purchase up to 1,100,000 shares of common stock. Gross proceeds from the offering were approximately $ 2.9 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company, with aggregate net proceeds of approximately $ 2.4 million. The closing of the offering occurred on September 15, 2023. Each September Common Stock Warrant is exercisable for a period of five years from the issuance date at an exercise price of $ 2.505 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis. Each September Pre-Funded Warrant is exercisable until exercised in full at an exercise price of $ 0.001 per share and may be exercised on a cashless basis. F- 17 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 The measurement of fair value of the September Pre-Funded Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at September 15, 2023, the date of issuance (i.e., share price of $ 1.84 , exercise price of $ 0.001 , term of 30 years beginning September 15, 2023 (as these do not have an expiration date), volatility of  146.89 %, risk-free rate of  4.42 %, and expected dividend rate of  0 %). The grant date fair value of the September Pre-Funded Warrants was estimated to be $ 1.0  million on September 15, 2023 and was reflected within additional paid-in capital as the September Pre-Funded Warrants were determined to be equity classified. The measurement of fair value of the September Common Stock Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at September 15, 2023, the date of issuance (i.e., share price of $ 1.84 , exercise price of $ 2.505 , term of  five years beginning September 15, 2023, volatility of  146.89 %, risk-free rate of  4.45 %, and expected dividend rate of  0 %). The grant date fair value of these September Common Stock Warrants was estimated to be $ 1.8  million on September 15, 2023 and was reflected within additional paid-in capital as the September Common Stock Warrants were determined to be equity classified. On various dates in September 2023, the September Investors exercised 495,050 of the September Pre-Funded Warrants for an aggregate of 495,050 shares of common stock for aggregate gross proceeds to the Company of $ 495 . In addition, pursuant to the terms of the September offering, the Company issued designees of the placement agent, Wainwright warrants (the “September Wainwright Warrants”) to purchase up to 55,000 shares of the Company’s common stock. The September Wainwright Warrants are exercisable for a period of five years from the commencement of sales at an exercise price of $ 3.2875 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis. As the September Wainwright Warrants were issued for services provided in facilitating the September offering, the Company recorded the fair value of such September Wainwright Warrants as an equity issuance cost on the issuance date. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at September 15, 2023, the date of issuance (i.e., share price of $ 1.84 , exercise price of $ 3.2875 , term of  five years beginning September 15, 2023, volatility of  146.89 %, risk-free rate of  4.45 %, and expected dividend rate of  0 %). 2024 On January 8, 2024, the Company issued 55,675 common shares in connection with the exercise of the remaining 55,675 September Pre-Funded Warrants that were issued in connection with a securities purchase agreement dated September 13, 2023. On March 27, 2024, the Company entered into an inducement offer agreement with a holder (the “Holder”) of certain of the Company’s existing warrants (the “January 2023 Existing Warrants”) to immediately exercise for cash an aggregate 2,500,000 of the January 2023 Existing Warrants to purchase shares of the Company’s common stock at a reduced exercise price of $ 1.6775 per share for gross proceeds to the Company of approximately $ 4.2 million before deducting placement agent fees and other offering expenses payable by the Company. The exercised January 2023 Existing Warrants were issued pursuant to a securities purchase agreement dated December 29, 2022 by and between the Company and the Holder. Each January 2023 Existing Warrant was exercisable for a period of five and one-half years from the issuance date at an original exercise price of $ 5.00 per share. As an inducement to such exercise, the Company agreed to issue new unregistered warrants to purchase up to 3,750,000 shares of the Company’s common stock at an exercise price of $ 1.50 per share (the “April 2024 Inducement Warrants”). The April 2024 Inducement Warrants are exercisable immediately upon issuance and will expire on July 3, 2028 . On April 1, 2024, the Holder exercised such warrants, and the Company issued the Holder 3,750,000 April 2024 Inducement Warrants. Additionally, in connection with the exercise of the January 2023 Existing Warrants, the Company issued 125,000 placement agent warrants to the designees of the placement agent, Wainwright, which are immediately exercisable and expire on July 3, 2028 at an exercise price of $ 2.0969 per share. F- 18 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 The amendment to the January 2023 Existing Warrants on March 27, 2024 to lower the exercise price thereof was considered a modification of the January 2023 Existing Warrants under the guidance of ASU 2021-04. The modification is consistent with the “Equity Issuance” classification under that guidance as the reason for the modification was to induce the holders to cash exercise their warrants, resulting in the exercise of the January 2023 Existing Warrants on April 1, 2024. On March 27, 2024, the Company calculated the total fair value of the consideration for the modification of the January 2023 Existing Warrants, which includes the incremental fair value of the January 2023 Existing Warrants (determined by comparing the fair values immediately prior to and immediately after the modification). The fair values were calculated using the Black-Scholes option-pricing model, and the Company determined that the total fair value of the consideration related to the modification of the January 2023 Existing Warrants amounted to $ 550,500 , which are considered offering costs and were netted against the net proceeds received by the warrant exercise under the guidance of ASU 2021-04. On April 1, 2024, in connection with the March 27, 2024 inducement offer agreement with the Holder of the January 2023 Existing Warrants, the Holder exercised the January 2023 Existing Warrants for cash at a reduced exercise price of $ 1.6775 per share resulting in gross proceeds to the Company of approximately $ 4.2 million (net proceeds of approximately $ 3.7 million, after deducting placement agent fees and other offering expenses of $ 0.5 million). In connection with such exercise, during the year ended December 31, 2024, the Company issued 2,500,000 shares of common stock upon the exercise of the January 2023 Existing Warrants. On April 1, 2024, in connection with the issuance of the April 2024 Inducement Warrants and the placement agent warrants, the Company calculated the fair value of such warrants using the Black-Scholes option-pricing model, and the Company determined that the aggregate total fair value of the April 2024 Inducement Warrants and placement agent warrants amounted to $ 4,166,800 , which are considered offering costs and were netted against the net proceeds received by the warrant exercise under the guidance of ASU 2021-04. The fair value of the January 2023 Existing Warrants on the modification date and the fair value of the April 2024 Inducement Warrants were estimated using the Black-Scholes option-pricing model with the following assumptions: March 27, 2024 to April 1, 2024 Exercise price $ 1.50 to $ 5.00 Term (years) 4.25 Expected stock price volatility 109.8 % Risk-free rate of interest 4.18 % to 4.34 % F- 19 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 A summary of warrant activity for the years ended December 31, 2024 and 2023 is as follows: Number of Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2022 402,840 $ 49.83 — 1.4 Issued 6,165,725 2.61 — 4.5 Exercised ( 2,355,050 ) — — — Outstanding as of December 31, 2023 4,213,515 7.01 — 4.5 Issued 3,875,000 1.52 — — Expired ( 329,597 ) 49.08 — — Exercised ( 2,555,675 ) 0.67 — — Outstanding as of December 31, 2024 5,203,243 2.62 — 3.52 Warrants exercisable as of December 31, 2024 5,203,243 $ 2.62 $ — 3.52 The Company has determined that the warrants should be accounted for as a component of stockholders’ equity. Common Shares As a result of exercising the December Pre-Funded Warrants on various dates in February 2023, the investor exercised all the December Pre-Funded Warrants for an aggregate of 1,860,000 shares of the Company’s common stock for aggregate net proceeds to the Company of $ 1,860 . On September 13, 2023, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which it sold (i) 549,275 shares of common stock and (ii) September Pre-Funded Warrants to purchase up to 550,725 shares of common stock at a purchase price of $ 2.63 per share of common stock and a purchase price of $ 2.629 per September Pre-Funded Warrant. Concurrently with the sale of common stock and/or the September Pre-Funded Warrants, pursuant to the securities purchase agreement, in a private placement, the Company issued and sold the September Common Stock Warrants to purchase up to 1,100,000 shares of common stock. Gross proceeds from the offering were approximately $ 2.9 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company, with aggregate net proceeds of approximately $ 2.4 million. The closing of the offering occurred on September 15, 2023. On January 8, 2024, the Company issued 55,675 common shares in connection with the exercise of 55,675 pre-funded warrants that were issued in connection with a securities purchase agreement dated September 13, 2023. During the year ended December 31, 2024, the Company issued 2,500,000 shares of its common stock in connection with the exercise of 2,500,000 December Common Stock Warrants. See Warrants section above. On November 8, 2024, the Company entered into the ATM Agreement with Wainwright under which the Company may offer and sell shares of its common stock having an aggregate sales price of up to $ 2,700,000 through Wainwright as the sales agent pursuant to the Company’s effective shelf registration statement on Form S-3, including an accompanying prospectus (File No. 333-272620), and a prospectus supplement dated November 8, 2024. Sales of shares of the Company’s common stock through Wainwright, if any, will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. Wainwright will use commercially reasonable efforts to sell shares of the Company’s common stock from time to time, based on instructions from the Company (including any price, time or size limits or other parameters or conditions the Company may impose). The Company will pay Wainwright a commission equal to 3.0 % of the aggregate gross proceeds from the sales of shares of the Company’s common stock sold through Wainwright under the ATM Agreement and will also reimburse Wainwright for certain specified expenses in connection with the ATM Agreement. The offering of shares pursuant to the ATM Agreement will terminate on the earlier of (1) the sale, pursuant to the ATM Agreement, of shares having an aggregate offering price of $ 2,700,000 and (2) the termination of the ATM Agreement by either the Company or Wainwright, as set forth therein. From November 8, 2024 to December 31, 2024, the Company issued 1,137,250 shares of its common stock for net proceeds of approximately $ 1.0 million pursuant to the ATM Agreement. F- 20 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 2018 Equity Incentive Plan On May 4, 2018, the Company’s board of directors adopted the Hoth Therapeutics, Inc. 2018 Equity Incentive Plan (the “2018 Plan”) initially reserving 40,000 shares of the Company’s common stock for issuance thereunder. The 2018 Plan became effective on May 14, 2018 upon written approval of the 2018 Plan by shareholders holding a majority of the Company’s voting capital. The compensation committee of the board of directors increased the number of shares reserved pursuant to the Company’s 2018 Equity Incentive Plan (“2018 Plan”) by 26,878 shares effective as of January 1, 2021, such that as of January 1, 2021, the Company had an aggregate of 66,878 shares of common stock reserved for issuance pursuant to the 2018 Plan. On June 24, 2021, at the annual meeting of shareholders, shareholders of the Company approved an amendment to the 2018 Plan to further increase the number of shares reserved for issuance thereunder from 66,878 shares to 146,878 shares. On February 2, 2022, the compensation committee of the board of directors further increased the number of shares reserved for issuance under the 2018 Plan from 146,878 shares to 156,878 shares. On January 11, 2023, the compensation committee of the board of directors further increased the number of shares reserved for issuance under the 2018 Plan from 156,878 shares to 166,878 shares. On January 4, 2024, the compensation committee of the board of directors further increased the number of shares reserved for issuance under the 2018 Plan from 166,878 shares to 176,878 shares. On January 6, 2025, the compensation committee of the board of directors further increased the number of shares reserved for issuance under the 2018 plan from 176,878 shares to 186,878 shares. As of December 31, 2024, there were 83,738 shares of Company common stock available for grant under the 2018 Plan. 2022 Equity Incentive Plan On March 24, 2022, the Company’s board of directors adopted the Hoth Therapeutics, Inc. 2022 Omnibus Equity Incentive Plan (the “2022 Plan”) initially reserving 96,000 shares of the Company’s common stock for issuance thereunder. The 2022 Plan became effective on June 23, 2022 upon approval of the 2022 Plan by the Company’s shareholders at the Company’s annual meeting of shareholders. On June 2, 2023, the Company’s board of directors approved the Hoth Therapeutics, Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan (the “Amended and Restated 2022 Plan”) which, among other things, increased the number of shares reserved under the plan by 495,317 shares, which Amended and Restated 2022 Plan was approved by stockholders on August 18, 2023. On May 15, 2024, the Company’s compensation committee recommended, and the board of directors approved an increase to the number of shares of common stock reserved for issuance under the Amended and Restated 2022 Plan by 500,000 shares from 51,317 shares to 551,317 shares (“2024 Increase”). The 2024 Increase was approved by shareholders of the Company on August 7, 2024. As of December 31, 2024, there were 78,317 shares of Company common stock available for grant under the Amended and Restated 2022 Plan. Restricted Stock Awards A summary of the Company’s restricted stock awards granted under the equity incentive plans during the years ended December 31, 2024 and 2023 is as follows: Number of Restricted Stock Awards Weighted Average Grant Day Fair Value Nonvested on December 31, 2022 3,384 3.16 Vested ( 1,691 ) 3.16 Nonvested on December 31, 2023 1,693 3.16 Vested ( 1,693 ) 3.16 Nonvested on December 31, 2024 — — F- 21 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 During the years ended December 31, 2024 and 2023, the Company recognized stock-based compensation of $ 2,543 and $ 7,734 , respectively, in connection with restricted stock awards. Stock Options On July 17, 2023, pursuant to and subject to the available number of shares reserved under the 2022 Plan, the Company issued an aggregate of 90,000 options to the Company’s employees and directors. The aggregate grant date fair value of these options was $ 216,428 , which was recorded as stock-based compensation during the year ended December 31, 2023. On January 5, 2024, pursuant to and subject to the available number of shares reserved under the Amended and Restated 2022 Plan, the Company issued options to the Company’s employees and directors to purchase up to 450,000 shares of the Company’s common stock at an exercise price of $ 1.36 per share. The options vested immediately and expire on January 5, 2034. The aggregate grant date fair value of these options was $ 512,685 , which was recorded as stock-based compensation during the year ended December 31, 2024. On August 19, 2024, pursuant to and subject to the available number of shares reserved under the Amended and Restated 2022 Plan, the Company issued options to the Company’s employees and directors to purchase up to 473,000 shares of the Company’s common stock at an exercise price of $ 0.7548 per share. The options vested immediately in full upon grant and expire on August 19, 2034. The aggregate grant date fair value of these options was $ 281,388 , which was recorded as stock-based compensation during the year ended December 31, 2024. The fair value of option grants was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions: Year Ended December 31, 2024 2023 Exercise price $ 0.7548 to $ 1.36 $ 2.59 Term (years) 5.0 10.0 Expected stock price volatility 106.65 % to 120.00 % 105.00 % Risk-free rate of interest 3.75 % to 4.02 % 4.02 % A summary of option activity under the Company’s equity incentive plans for the years ended December 31, 2024 and 2023 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2022 104,651 $ 49.80 $ — 8.3 Employee options issued 90,000 2.59 — 9.5 Expired ( 25,289 ) 46.10 — — Outstanding as of December 31, 2023 169,362 26.78 — 8.4 Employee options issued 923,000 1.05 — — Expired ( 2,000 ) 147.0 — — Outstanding as of December 31, 2024 1,090,362 $ 4.78 $ — 9.1 Options vested and exercisable as of December 31, 2024 1,090,362 $ 4.78 $ — 9.1 A summary of stock options outstanding at December 31, 2024 by price range is as follows: Options outstanding and exercisable Range of Exercise Prices Number of Shares Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Up to $ 2.59 1,013,000 $ 9.3 1.19 $ 14.75 to $ 76.25 62,562 6.7 32.95 Above $ 76.25 14,800 $ 5.0 131.50 Options outstanding and exercisable as of December 31, 2024 1,090,362 $ 9.1 4.78 F- 22 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 All stock compensation associated with the amortization of employee stock option expense was recorded as a component of general and administrative expenses in the consolidated statements of operations and comprehensive loss. Estimated future stock-based compensation expense relating to unvested stock options is $ 0 . Stock Based Compensation Stock based compensation expense for the years ended December 31, 2024 and 2023 was as follows: Year Ended December 31, 2024 2023 Employee stock option awards $ 794,073 $ 182,522 Non-employee restricted stock awards 2,543 7,734 Non-employee stock warrant awards (a) 7,661 26,172 $ 804,277 $ 216,428 (a) Represents accretion of stock based compensation expense for non-employee stock warrants issued in 2021. For the years ended December 31, 2024 and 2023, the amount of stock-based compensation expense included within research and development and general and administrative expenses was as follows: Year Ended December 31, 2024 2023 Research and development $ 7,661 $ 26,172 General and administrative 796,616 190,256 $ 804,277 $ 216,428 NOTE 6 – Commitments and Contingencies Office Lease Effective November 2023, the Company leased office space for a two-year term. The Company’s office lease contained a renewal option. The Company evaluated several factors in assessing whether there is reasonable certainty that the Company will exercise its contractual renewal option concluding that it is not reasonably certain to exercise such option. As it is not reasonably certain to be exercised, the Company excluded the renewal term in determining the lease term used in calculating the right-of-use asset and lease liability. In December 2024, the landlord notified the Company that it will be closing its operations at the Company’s location and offering to relocate the Company to a new location. The Company agreed to relocate and accordingly, on December 9, 2024, the Company and the landlord entered into a new lease agreement (the “December 2024 Lease”). Pursuant to the December 2024 Lease, effective December 20, 2024, the Company leased office space for a term of 14 months, expiring on February 28, 2026. Pursuant to such lease agreement, the Company is required to pay a monthly base rent of $ 2,732 from March 1, 2025 through February 2026. In connection with December 2024 Lease, in December 2024, the Company increased right-of-use assets and lease liabilities by $ 31,075 and removed all remaining right-of-use assets and lease liabilities associated with the November 2023 lease. The table below presents certain information related to the Company’s lease costs, which are included in general and administrative expenses in the accompanying consolidated statements of operation and comprehensive loss: Year Ended December 31, 2024 2023 Operating lease expense $ 34,000 $ 5,464 Short term lease expense 19,135 33,351 Total lease cost $ 53,135 $ 38,815 F- 23 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Right-of-use asset for operating leases were recorded in the consolidated balance sheets as follows: December 31, 2024 December 31, 2023 Office lease right-of-use asset $ 31,075 $ 59,698 Less accumulated amortization - ( 4,533 ) Total right-of-use asset, net $ 31,075 $ 55,165 Operating lease liability for operating leases were recorded in the consolidated balance sheets as follows: December 31, 2024 December 31, 2023 Current portion of operating lease liability $ 28,366 $ 28,839 Long-term portion of operating lease liability 2,709 26,326 Total operating lease liability $ 31,075 $ 55,165 Supplemental cash flow information related to the Company’s leases for the year ended December 31, 2024 were as follows: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 24,090 The weighted-average remaining lease term for the operating lease is 1.2 years and the weighted-average incremental borrowing rate is 10 % as of December 31, 2024 and 2023. As of December 31, 2024, future annual minimum lease payments required under operating leases are as follows: 2025 $ 30,052 2026 2,732 Total minimum lease payments $ 32,784 Less: effects of discounting ( 1,709 ) Present value of future minimum lease payments $ 31,075 NOTE 7 – Income Taxes The table below presents the components of the provision for taxes: The Company’s provision is primarily driven by the full valuation allowance in 2024 and 2023. As of December 31, 2024 2023 Current (As Restated) U.S. Federal $ - $ - U.S. State - - U.S. Foreign - - Total current provision Deferred - - U.S. Federal - - U.S. State - - U.S. Foreign - - Total deferred benefit - - Change in valuation allowance - - Total provision for income taxes $ - $ - F- 24 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 At December 31, 2024 and 2023, the tax effects of the temporary differences and carryforwards that give rise to deferred tax assets consist of the following: As of December 31, 2024 2023 Deferred tax assets (As Restated) Net operating loss carryforwards $ 13,388,457 $ 11,737,071 Capitalized research costs 3,044,801 2,343,014 Equity based compensation 681,546 549,587 Licenses acquired 254,947 266,091 Accruals and other temporary differences 302,231 297,949 Total deferred tax assets 17,671,982 15,193,712 Less valuation allowance ( 17,671,982 ) ( 15,193,712 ) Deferred tax assets, net of allowance $ - $ - A reconciliation of the statutory income tax rates and the Company’s effective tax rate for the years ended December 31, 2024 and 2023 is as follows: Years Ended December 31, 2024 2023 Statutory federal income tax rate 21.0 % 21.0 % State taxes, net of federal benefit 9.9 % 10.3 % Impact of non-U.S. earnings 0.0 % 0.0 % Permanent items 0.0 % 0.0 % Credits 0.0 % 0.8 % Equity compensation 0.0 % 0.0 % Foreign rate differential 0.1 % 0.1 % Previous tax year adjustment ( 0.5 )% ( 1.2 )% Other 0.0 % 0.0 % Change in valuation allowance ( 30.5 )% ( 31.0 )% Total 0.0 % 0.0 % The Company has determined, based upon available evidence, that it is more likely than not that the net deferred tax assets will not be realized and, accordingly, has provided a full valuation allowance against its net deferred tax assets. F- 25 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 As of December 31, 2024 and 2023, the Company has Federal net operating loss carryforwards of approximately $ 42.0 million and $ 36.8 million, respectively, available to reduce future taxable income, if any, for Federal tax purposes. Approximately $ 1.5 million of Federal net operating losses can be carried forward to future tax years and expire in 2037. The Federal net operating loss generated during the years ended after December 31, 2017 of approximately $ 40.5 million can be carried forward indefinitely; however, the deduction for net operating losses incurred in tax years beginning after January 1, 2018 is limited to 80 % of annual taxable income. In ad dition, the Company had approximately $ 0.6 million and $ 0.5 million of net operating losses at its subsidiary located in Australia, as of December 31, 2024 and 2023, respectively. As required by the 2017 Tax Cuts and Jobs Act and effective in 2022, the deferred tax asset as of December 31, 2024 and 2023, included $ 3.0 million and $ 2.3 million related to the mandatory capitalization of research and development expenses, respectively. On August 16, 2022, the Inflation Reduction Act of 2022 (“IRA”) was signed into law. The IRA increased and modified the qualified small business (“QSB”) payroll tax credit for increasing research activities. Provision 13902 of the IRA of 2022 increased the maximum amount of payroll tax research credit that a QSB can elect to apply against payroll tax liability from $ 250,000 to $ 500,000 for tax years beginning after December 31, 2022. This payroll tax credit is a creditable tax credit against the employer’s portion of social security taxes, and the IRA also modified IRC 3111(f) to allow a portion of the payroll tax credit to apply against the employer’s portion of Medicare tax. For the year ended December 31, 2023, the Company recorded $ 0.1 million of other income for the payroll tax credit and $ 0.2 million is still outstanding. The remaining research credit carryforward of $ 0.2 million will be utilized in the future as an offset against payroll taxes at the time the payroll tax is incurred. The utilization of the Company’s net operating loss carryforwards and research tax credit carryovers could be subject to annual limitations under Section 382 and 383 of the Internal Revenue Code of 1986, as amended (the “Code”), and similar state tax provisions, due to ownership change limitations that may have occurred previously or that could occur in the future. These ownership changes limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382 and 383 of the Code, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percent points over a three-year period. The Company has not conducted an analysis of an ownership change under Section 382 of the Code. To the extent that a study is completed and an ownership change is deemed to occur, the Company’s net operating losses and tax credits could be limited. At December 31, 2024 and 2023, the Company did not have any significant uncertain tax positions. The Company will recognize interest and penalties related to uncertain tax positions, as applicable, in income tax expense. As of December 31, 2024 and 2023, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statements of operations. The Company does not anticipate a material change to unrecognized tax benefits in the next twelve months. All of the Company’s tax years will remain open for examination by the Federal and state tax authorities from the date of utilization of the net operating loss. Management asserts that its foreign earnings are permanently reinvested, and therefore, have not provided deferred taxes on foreign cash. Additionally, no additional income taxes have been provided for any remaining undistributed foreign earnings not subject to the transition tax, or any additional outside basis differences inherent in our foreign subsidiaries, as these amounts continue to be indefinitely reinvested in foreign operations. The Company will continue to monitor the foreign cash position as they maintain the assertion that foreign earnings are permanently reinvested. F- 26 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 NOTE 8 – Restatement of Previously Issued Audited and Unaudited Financial Statements During the preparation of the Company’s 2024 audited consolidated financial statements and notes thereto, the Company concluded that there were material research and development expenses and related balance sheet errors in its previously issued audited consolidated financial statements as of and for the year ended December 31, 2023, 2022 and 2021, and there were material research and development expenses and related balance sheet errors in its previously issued unaudited condensed consolidated financial statements as of and for each of the quarterly and year to date periods ended March 31, 2024 and 2023, June 30, 2024 and 2023, and September 30, 2024 and 2023, relating to the recording of prepaid expenses, and the timing of recognition of research and development expenses. 1) The Company noted the following items were improperly recorded as of December 31, 2023, 2022 and 2021, and for the year ended December 31, 2023 As of December 31, 2023, 2022 and 2021, the Company’s consolidated balance sheets did not reflect prepa id expenses and other current assets related to advance payments made in 2022 and 2021 for clinical studies. These errors in the accounting for prepaid expenses and other current assets and research and development expenses resulted in an understatement of prepaid assets and other current assets of $ 722,765 , $ 983,497 , and $ 972,567 as of December 31, 2023, 2022 and 2021, respectively, an understatement of research and development expenses, operating expenses and net loss of $ 260,732 for the year ended December 31, 2023, and an overstatement of research and development expenses, operating expenses and net loss of $ 10,929 and $ 972,567 for the years ended December 31, 2022 and 2021, respectively. The December 31, 2022 understatement of prepaid expenses and other current assets of $ 983,497 and the overstatement of research and development expenses of $ 10,929 and $ 972,567 during the years ended December 31, 2022 and 2021, respectively, which aggregated to $ 983,497 , was corrected by increasing prepaid expenses and other current assets and decreasing accumulated deficit as of December 31, 2022 by $ 983,497 , as reflected in the consolidated statements of changes in stockholders’ equity as of December 31, 2022. 2) The Company noted the following items were improperly recorded as of March 31, 2024 and 2023, and during the three months ended March 31, 2024 and 2023: ● As of March 31, 2024, prepaid expenses and other current assets were understated by $ 617,019 and for the three months ended March 31, 2024, research and development expenses were understated by $ 105,746 . ● As of March 31, 2023, prepaid expenses and other current assets were understated by $ 931,456 and for the three months ended March 31, 2023, research and development expenses were understated by $ 52,041 . 3) The Company noted the following items were improperly recorded as of June 30, 2024 and 2023, and during the three and six months ended June 30, 2024 and 2023: ● As of June 30, 2024, prepaid expenses and other current assets were understated by $ 539,329 and for the three and six months ended June 30, 2024, research and development expenses were understated by $ 77,690 and $ 183,436 , respectively. ● As of June 30, 2023, prepaid expenses and other current assets were understated by $ 908,416 and for the three and six months ended June 30, 2023, research and development expenses were understated by $ 23,040 and $ 75,081 , respectively. 4) The Company noted the following items were improperly recorded as of September 30, 2024 and 2023, and during the three and nine months ended September 30, 2024 and 2023: ● As of September 30, 2024, prepaid expenses and other current assets were understated by $ 442,365 and for the three and nine months ended September 30, 2024, research and development expenses were understated by $ 96,964 and $ 280,400 , respectively. ● As of September 30, 2023, prepaid expenses and other current assets were understated by $ 817,340 and for the three and nine months ended September 30, 2023, research and development expenses were understated by $ 91,076 and $ 166,157 , respectively. F- 27 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 For all periods presented, the errors in the accounting for research and development expenses resulted in an understatement of prepaid assets and other current assets and an understatement of research and development expenses, operating expenses and net losses for the periods presented, respectively. As a result of such errors, the Company concluded that the previously issued 2023 consolidated financial statements and the previously issued interim periods during 2024 and 2023 were materially misstated and has restated herein its previously issued audited consolidated financial statements for the year ended December 31, 2023, and its unaudited condensed consolidated financial statements for each interim period within the fiscal years ended December 31, 2024 and 2023. The restatement corrections impact certain components within operating cash flows of the respective consolidated statements of cash flows. Total operating cash flows, investing activities, financing activities, and cash and cash equivalents are unchanged as a result of the restatements. The following tables present the amounts previously reported, the restatement impact and the amount as restated. The 2024 and 2023 quarterly restatements will be effective with the filing of our future 2025 unaudited interim condensed financial statement filings in Quarterly Reports on Form 10-Q. The values “as reported” on the following respective consolidated financial statements were derived from: 1) Our Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 28, 2024; 2) Our Quarterly Report on Form 10-Q for the period ended March 31, 2024 filed on May 14, 2024; 3) Our Quarterly Report on Form 10-Q for the period ended June 30, 2024 filed on August 9, 2024; 4) Our Quarterly Report on Form 10-Q for the period ended September 30, 2024 filed on November 12, 2024; 5) Our Quarterly Report on Form 10-Q for the period ended March 31, 2023 filed on May 15, 2023; 6) Our Quarterly Report on Form 10-Q for the period ended June 30, 2023 filed on August 11, 2023; and 7) Our Quarterly Report on Form 10-Q for the period ended September 30, 2023 filed on November 13, 2023. F- 28 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Reconciliation of the Original and Restated Consolidated Balance Sheet As of December 31, 2022 As Previously Reported Restatement Impacts As Restated ASSETS CURRENT ASSETS: Prepaid expenses and other current assets $ 88,450 $ 983,497 $ 1,071,947 Total Current Assets 6,726,381 983,497 7,709,878 Total Assets $ 6,759,381 $ 983,497 $ 7,742,878 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: STOCKHOLDERS’ EQUITY: Accumulated deficit $ ( 45,099,116 ) $ 983,497 $ ( 44,115,619 ) Total Stockholders’ Equity 5,121,650 983,497 6,105,147 Total Liabilities and Stockholders’ Equity $ 6,759,381 $ 983,497 $ 7,742,878 As of December 31, 2023 As Previously Reported Restatement Impacts As Restated ASSETS CURRENT ASSETS: Prepaid expenses and other current assets $ 135,361 $ 722,765 $ 858,126 Total Current Assets 9,427,713 722,765 10,150,478 Total Assets $ 9,520,278 $ 722,765 $ 10,243,043 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: STOCKHOLDERS’ EQUITY: Accumulated deficit $ ( 52,944,506 ) $ 722,765 $ ( 52,221,741 ) Total Stockholders’ Equity 8,815,295 722,765 9,538,060 Total Liabilities and Stockholders’ Equity $ 9,520,278 $ 722,765 $ 10,243,043 Consolidated Statement of Operations and Comprehensive Loss For the Year Ended December 31, 2023 As Previously Reported Restatement Impacts As Restated Research and development expense $ 3,480,053 $ 260,732 $ 3,740,785 Total operating expenses 7,692,242 260,732 7,952,974 LOSS FROM OPERATIONS ( 7,692,242 ) ( 260,732 ) ( 7,952,974 ) NET LOSS $ ( 7,845,390 ) $ ( 260,732 ) $ ( 8,106,122 ) NET LOSS PER COMMON SHARE: Basic and diluted $ ( 2.30 ) $ ( 0.08 ) $ ( 2.38 ) COMPREHENSIVE LOSS: Total comprehensive loss $ ( 7,840,136 ) $ ( 260,732 ) $ ( 8,100,868 ) F- 29 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Reconciliation of the Original and Restated Consolidated Statements of Stockholders’ Equity For the Year Ended December 31, 2023 As Previously Reported Restatement Impacts As Restated Accunulated Deficit ACTIVITIES: Net loss $ ( 7,845,390 ) $ ( 260,732 ) $ ( 8,106,122 ) Changes in operating assets and liabilities: Prepaid expenses ( 47,300 ) 260,732 213,432 NET CASH USED IN OPERATING ACTIVITIES ( 8,447,094 ) - ( 8,447,094 ) Reconciliation of the Original and Restated Consolidated Statements of Cash Flows For the Year Ended December 31, 2023 As Previously Reported Restatement Impacts As Restated CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 7,845,390 ) $ ( 260,732 ) $ ( 8,106,122 ) Changes in operating assets and liabilities: Prepaid expenses ( 47,300 ) 260,732 213,432 NET CASH USED IN OPERATING ACTIVITIES ( 8,447,094 ) - ( 8,447,094 ) Reconciliation of the Original and Restated Consolidated Balance Sheet As of March 31, 2024 As Previously Reported Restatement Impacts As Restated ASSETS CURRENT ASSETS: Prepaid expenses and other current assets $ 293,160 $ 617,019 $ 910,179 Total Current Assets 8,406,288 617,019 9,023,307 Total Assets $ 8,491,329 $ 617,019 $ 9,108,348 LIABILITIES AND STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY: Accumulated deficit $ ( 54,985,289 ) $ 617,019 $ ( 54,368,270 ) Total Stockholders’ Equity 7,832,594 617,019 8,449,613 Total Liabilities and Stockholders’ Equity $ 8,491,329 $ 617,019 $ 9,108,348 F- 30 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Reconciliation of the Original and Restated Consolidated Statement of Operations and Comprehensive Loss For the Three Months Ended March 31, 2024 As Previously Reported Restatement Impacts As Restated OPERATING COSTS AND EXPENSES: Research and development expense $ 465,896 $ 105,746 $ 571,642 General and administrative expenses 1,588,262 - 1,588,262 Total operating expenses 2,054,158 105,746 2,159,904 LOSS FROM OPERATIONS ( 2,054,158 ) ( 105,746 ) ( 2,159,904 ) NET LOSS $ ( 2,040,783 ) $ ( 105,746 ) $ ( 2,146,529 ) NET LOSS PER COMMON SHARE: Basic and diluted $ ( 0.46 ) $ ( 0.02 ) $ ( 0.49 ) COMPREHENSIVE LOSS: Total comprehensive loss $ ( 2,046,551 ) $ ( 105,746 ) $ ( 2,152,297 ) Reconciliation of the Original and Restated Consolidated Statements of Cash Flows For the Three Months Ended March 31, 2024 As Previously Reported Restatement Impacts As Restated CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 2,040,783 ) $ ( 105,746 ) $ ( 2,146,529 ) Prepaid expenses ( 157,799 ) 105,746 ( 52,053 ) NET CASH USED IN OPERATING ACTIVITIES ( 1,723,956 ) - ( 1,723,956 ) F- 31 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Reconciliation of the Original and Restated Consolidated Balance Sheet As of June 30, 2024 As Previously Reported Restatement Impacts As Restated ASSETS CURRENT ASSETS: Prepaid expenses and other current assets $ 299,708 $ 539,329 $ 839,037 Total Current Assets 9,954,545 539,329 10,493,874 Total Assets $ 10,032,468 $ 539,329 $ 10,571,797 LIABILITIES AND STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY: Accumulated deficit $ ( 56,617,763 ) $ 539,329 $ ( 56,078,434 ) Total Stockholders’ Equity 9,340,608 539,329 9,879,937 Total Liabilities and Stockholders’ Equity $ 10,032,468 $ 539,329 $ 10,571,797 Reconciliation of the Original and Restated Consolidated Statement of Operations and Comprehensive Loss For the Three Months Ended June 30, 2024 For the Six Months Ended June 30, 2024 As Previously Reported Restatement Impacts As Restated As Previously Reported Restatement Impacts As Restated OPERATING COSTS AND EXPENSES: Research and development expense 566,335 77,690 644,025 1,032,231 183,436 1,215,667 Total operating expenses 1,645,839 77,690 1,723,529 3,699,997 183,436 3,883,433 LOSS FROM OPERATIONS ( 1,645,839 ) ( 77,690 ) ( 1,723,529 ) ( 3,699,997 ) ( 183,436 ) ( 3,883,433 ) NET LOSS $ ( 1,632,474 ) $ ( 77,690 ) $ ( 1,710,164 ) $ ( 3,673,257 ) $ ( 183,436 ) $ ( 3,856,693 ) NET LOSS PER COMMON SHARE: Basic and diluted $ ( 0.24 ) $ ( 0.01 ) $ ( 0.25 ) $ ( 0.65 ) $ ( 0.03 ) $ ( 0.68 ) COMPREHENSIVE LOSS: Total comprehensive loss $ ( 1,630,840 ) $ ( 77,690 ) $ ( 1,708,530 ) $ ( 3,677,391 ) $ ( 183,436 ) $ ( 3,860,827 ) F- 32 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Reconciliation of the Original and Restated Consolidated Statements of Cash Flows For the Six Months Ended June 30, 2024 As Previously Reported Restatement Impacts As Restated CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 3,673,257 ) $ ( 183,436 ) $ ( 3,856,693 ) Changes in operating assets and liabilities: Prepaid expenses ( 164,347 ) 183,436 19,089 NET CASH USED IN OPERATING ACTIVITIES ( 3,315,681 ) - ( 3,315,681 ) Reconciliation of the Original and Restated Consolidated Balance Sheet As of September 30, 2024 As Previously Reported Restatement Impacts As Restated ASSETS CURRENT ASSETS: Prepaid expenses and other current assets $ 214,021 $ 442,365 $ 656,386 Total Current Assets 8,236,784 442,365 8,679,149 Total Assets $ 8,307,410 $ 442,365 $ 8,749,775 LIABILITIES AND STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY: Accumulated deficit ( 58,749,816 ) 442,365 ( 58,307,451 ) Total Stockholders’ Equity 7,494,377 442,365 7,936,742 Total Liabilities and Stockholders’ Equity $ 8,307,410 $ 442,365 $ 8,749,775 F- 33 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Reconciliation of the Original and Restated Consolidated Statement of Operations and Comprehensive Los For the Three Months Ended September 30, 2024 For the Nine Months Ended September 30, 2024 As Previously Reported Restatement Impacts As Restated As Previously Reported Restatement Impacts As Restated OPERATING COSTS AND EXPENSES: Research and development expense $ 897,510 $ 96,964 $ 994,474 $ 1,929,741 $ 280,400 $ 2,210,141 Total operating expenses 2,132,253 96,964 2,229,217 5,832,250 280,400 6,112,650 LOSS FROM OPERATIONS ( 2,132,253 ) ( 96,964 ) ( 2,229,217 ) ( 5,832,250 ) ( 280,400 ) ( 6,112,650 ) NET LOSS $ ( 2,132,053 ) $ ( 96,964 ) $ ( 2,229,017 ) $ ( 5,805,310 ) $ ( 280,400 ) $ ( 6,085,710 ) NET LOSS PER COMMON SHARE: Basic and diluted $ ( 0.31 ) $ ( 0.01 ) $ ( 0.32 ) $ ( 0.96 ) $ ( 0.05 ) $ ( 1.00 ) COMPREHENSIVE LOSS: Total comprehensive loss $ ( 2,129,563 ) $ ( 96,964 ) $ ( 2,226,527 ) $ ( 5,806,954 ) $ ( 280,400 ) $ ( 6,087,354 ) Reconciliation of the Original and Restated Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2024 As Previously Reported Restatement Impacts As Restated CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 5,805,310 ) $ ( 280,400 ) $ ( 6,085,710 ) Changes in operating assets and liabilities: - Prepaid expenses ( 78,660 ) 280,400 201,740 NET CASH USED IN OPERATING ACTIVITIES ( 4,950,245 ) - ( 4,950,245 ) F- 34 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Reconciliation of the Original and Restated Consolidated Balance Sheet As of March 31, 2023 As Previously Reported Restatement Impacts As Restated ASSETS CURRENT ASSETS: Prepaid expenses and other current assets $ 193,693 $ 931,456 $ 1,125,149 Total Current Assets 13,428,592 931,456 14,360,048 Total Assets $ 13,461,592 $ 931,456 $ 14,393,048 LIABILITIES AND STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY: Accumulated deficit $ ( 47,282,623 ) $ 931,456 $ ( 46,351,167 ) Total Stockholders’ Equity 11,865,533 931,456 12,796,989 Total Liabilities and Stockholders’ Equity $ 13,461,592 $ 931,456 $ 14,393,048 Reconciliation of the Original and Restated Consolidated Statement of Operations and Comprehensive Loss For the Three Months Ended March 31, 2023 As Previously Reported Restatement Impacts As Restated OPERATING COSTS AND EXPENSES: Research and development expense $ 890,845 $ 52,041 $ 942,886 Total operating expenses 2,192,817 52,041 2,244,858 LOSS FROM OPERATIONS ( 2,192,817 ) ( 52,041 ) ( 2,244,858 ) NET LOSS $ ( 2,183,507 ) $ ( 52,041 ) $ ( 2,235,548 ) NET LOSS PER COMMON SHARE: Basic and diluted $ ( 0.88 ) $ ( 0.02 ) $ ( 0.90 ) COMPREHENSIVE LOSS: Total comprehensive loss $ ( 2,178,137 ) $ ( 52,041 ) $ ( 2,230,178 ) F- 35 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Reconciliation of the Original and Restated Consolidated Statements of Cash Flows For the Three Months Ended March 31, 2023 As Previously Reported Restatement Impacts As Restated CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 2,183,507 ) $ ( 52,041 ) $ ( 2,235,548 ) Changes in operating assets and liabilities: Prepaid expenses ( 96,244 ) 52,041 ( 44,203 ) NET CASH USED IN OPERATING ACTIVITIES ( 2,289,418 ) - ( 2,289,418 ) Reconciliation of the Original and Restated Consolidated Balance Sheet As of June 30, 2023 As Previously Reported Restatement Impacts As Restated ASSETS CURRENT ASSETS: Prepaid expenses and other current assets 314,881 908,416 1,223,297 Total Current Assets 11,884,250 908,416 12,792,666 Total Assets $ 11,917,250 $ 908,416 $ 12,825,666 LIABILITIES AND STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY: Accumulated deficit $ ( 49,155,654 ) $ 908,416 $ ( 48,247,238 ) Total Stockholders’ Equity 9,951,162 908,416 10,859,578 Total Liabilities and Stockholders’ Equity $ 11,917,250 $ 908,416 $ 12,825,666 F- 36 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Reconciliation of the Original and Restated Consolidated Statement of Operations and Comprehensive Loss For the Three Months Ended June 30, 2023 For the Six Months Ended June 30, 2023 As Previously Reported Restatement Impacts As Restated As Previously Reported Restatement Impacts As Restated OPERATING COSTS AND EXPENSES: Research and development expense $ 640,959 $ 23,040 $ 663,999 $ 1,531,804 $ 75,081 $ 1,606,885 Total operating expenses 1,708,629 23,040 1,731,669 3,901,446 75,081 3,976,527 LOSS FROM OPERATIONS ( 1,708,629 ) ( 23,040 ) ( 1,731,669 ) ( 3,901,446 ) ( 75,081 ) ( 3,976,527 ) NET LOSS $ ( 1,873,031 ) $ ( 23,040 ) $ ( 1,896,071 ) $ ( 4,056,538 ) $ ( 75,081 ) $ ( 4,131,619 ) NET LOSS PER COMMON SHARE: Basic and diluted $ ( 0.57 ) $ ( 0.00 ) $ ( 0.57 ) $ ( 1.40 ) $ ( 0.03 ) $ ( 1.43 ) COMPREHENSIVE LOSS: Net loss $ ( 1,873,031 ) $ ( 23,040 ) $ ( 1,896,071 ) $ ( 4,056,538 ) $ ( 75,081 ) $ ( 4,131,619 ) Total comprehensive loss $ ( 1,924,119 ) $ ( 23,040 ) $ ( 1,947,159 ) $ ( 4,102,256 ) $ ( 75,081 ) $ ( 4,177,337 ) Reconciliation of the Original and Restated Consolidated Statements of Cash Flows For the Six Months Ended June 30, 2023 As Previously Reported Restatement Impacts As Restated CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 4,056,538 ) $ ( 75,081 ) $ ( 4,131,619 ) Prepaid expenses ( 227,391 ) 75,081 ( 152,310 ) NET CASH USED IN OPERATING ACTIVITIES $ ( 3,739,115 ) $ - $ ( 3,739,115 ) F- 37 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Reconciliation of the Original and Restated Consolidated Balance Sheet As of September 30, 2023 As Previously Reported Restatement Impacts As Restated ASSETS CURRENT ASSETS: Prepaid expenses and other current assets $ 200,328 $ 817,340 $ 1,017,668 Total Current Assets 12,053,137 817,340 12,870,477 Total Assets $ 12,086,137 $ 817,340 $ 12,903,477 LIABILITIES AND STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY: Accumulated deficit $ ( 51,242,237 ) $ 817,340 $ ( 50,424,897 ) Total Stockholders’ Equity 10,507,268 817,340 11,324,608 Total Liabilities and Stockholders’ Equity $ 12,086,137 $ 817,340 $ 12,903,477 Reconciliation of the Original and Restated Consolidated Statement of Operations and Comprehensive Loss For the Three Months Ended September 30, 2023 For the Nine Months Ended September 30, 2023 As Previously Reported Restatement Impacts As Restated As Previously Reported Restatement Impacts As Restated OPERATING COSTS AND EXPENSES: Research and development expense $ 1,246,061 $ 91,076 $ 1,337,137 $ 2,777,865 $ 166,157 $ 2,944,022 Total operating expenses 2,092,980 91,076 2,184,056 5,994,426 166,157 6,160,583 LOSS FROM OPERATIONS ( 2,092,980 ) ( 91,076 ) ( 2,184,056 ) ( 5,994,426 ) ( 166,157 ) ( 6,160,583 ) NET LOSS $ ( 2,086,583 ) $ ( 91,076 ) $ ( 2,177,659 ) $ ( 6,143,121 ) $ ( 166,157 ) $ ( 6,309,278 ) NET LOSS PER COMMON SHARE: Basic and diluted $ ( 0.60 ) $ ( 0.03 ) $ ( 0.63 ) $ ( 1.99 ) $ ( 0.05 ) $ ( 2.04 ) COMPREHENSIVE LOSS: Total comprehensive loss $ ( 2,040,122 ) $ ( 91,076 ) $ ( 2,131,198 ) $ ( 6,142,378 ) $ ( 166,157 ) $ ( 6,308,535 ) Reconciliation of the Original and Restated Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2023 As Previously Reported Restatement Impacts As Restated CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 6,143,121 ) $ ( 166,157 ) $ ( 6,309,278 ) Prepaid expenses ( 141,085 ) 166,157 25,072 NET CASH USED IN OPERATING ACTIVITIES ( 5,375,695 ) - ( 5,375,695 ) F- 38 HOTH THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 NOTE 9 – Subsequent Events The Company has evaluated subsequent events and transactions that occurred up to the date the consolidated financial statements were issued. Based upon this review, except for as noted below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements. On January 6, 2025, the compensation committee of the board of directors further increased the number of shares reserved for issuance under the 2018 Plan from 176,878 shares to 186,878 shares. On January 7, 2025, the Company issued 3,750,000 common shares in connection with the exercise of the 3,750,000 April 2024 Inducement Warrants for cash proceeds of $ 5,625,000 . On January 7, 2025 through March 5, 2025, pursuant to the ATM Agreement (See Note 5), the Company issued an aggregate of 927,968 shares of its common stock for net proceeds of $ 1,470,435 . On January 13, 2025, the Company entered into a Patent Application Acquisition Agreement with Med30, LLC (the “Seller”), whereby the Seller sold, conveyed, assigned and transferred to the Company all of Seller’s right, title, and interest in and to certain patent applications and associated rights, subject to the terms and conditions set forth in such agreement for a cash payment of $ 400,000 and the issuance of 450,000 shares of the Company’s common stock. On January 14, 2025, pursuant to and subject to the available number of shares reserved under the 2018 Plan, the Company issued options to the Company’s Chief Executive Officer to purchase up to 93,000 shares of the Company’s common stock at an exercise price of $ 1.55 per share. Additionally, on January 14, 2025, pursuant to and subject to the available number of shares reserved under the 2022 Plan, the Company issued options to the Company’s Chief Executive Officer and an employee to purchase up to 77,000 shares of the Company’s common stock at an exercise price of $ 1.55 per share. The options vested immediately in full upon grant and expire on January 14, 2035. The aggregate grant date fair value of these options was $ 219,283 , which was recorded as stock-based compensation in January 2025. On December 23, 2024, the Company provided notice to Isoprene Pharmaceutical, Inc. (“Isoprene”) of its intent to terminate the exclusive license agreement (the “Isoprene Agreement”) by and between the Company and Isoprene dated July 2, 2021. The Isoprene Agreement terminated on March 23, 2025. F- 39 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS AND FINANCIAL DISCLOSURE None.